Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- The GS934 study demonstrated superior virologic activity with emtricitabine/tenofovir DF vs lamivudine/zidovudine, with 84% vs 73% of patients, respectively, achieving HIV-1 RNA < 400 copies/mL at Week 48 (P = .002)[Gallant 2006]
- Emtricitabine/tenofovir DF is a recommended NRTI pair for first-line therapy in the US DHHS guidelines (Management Guidelines)[DHHS ART] and the EACS guidelines (Management Guidelines)[EACS ART]
- Emtricitabine/tenofovir AF is preferred over emtricitabine/tenofovir DF in the IAS-USA guidelines, although the guidance panel notes that emtricitabine/tenofovir DF is an effective and generally well-tolerated option when tenofovir AF is not available (Management Guidelines)[IAS-USA ART]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Initial Antiretroviral Therapy, Tropism